Inhibitory effect of reserpine on dopamine transporter function

European Journal of Pharmacology

Volumn 456, Issue 1-3, 2002, Pages 39-43

  Metzger, Ryan R ^a   Brown, Jeffrey M ^b   Sandoval, Verónica ^b   Rau, Kristi S ^b   Elwan, Mohamed A ^c   Miller, Gary W ^c   Hanson, Glen R ^a,b   Fleckenstein, Annette E ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Dopamine transporter; Reserpine; Striatum; VMAT 2 (vesicular monoamine transporter 2)

Indexed keywords

CARRIER PROTEIN; DOPAMINE; DOPAMINE TRANSPORTER; MEMBRANE PROTEIN; NERVE PROTEIN; NEUROPEPTIDE; RESERPINE; TRITIUM; VESICULAR AMINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ANIMAL; ARTICLE; CELL CULTURE; DRUG EFFECT; GENETICS; HUMAN; MALE; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT; SYNAPTOSOME; TIME; TRANSPORT AT THE CELLULAR LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; DRUG UPTAKE; KNOCKOUT MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STRAIN DIFFERENCE; WILD TYPE;

ANIMALS; BIOLOGICAL TRANSPORT; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NEUROPEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RESERPINE; SYNAPTOSOMES; TIME FACTORS; TRITIUM; TUMOR CELLS, CULTURED; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 0037027918     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02647-X     Document Type: Article

References (17)

1. Berman S.B., Zigmond M.J., Hastings T.G. Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J. Neurochem. 67:1996;593-600.
2. Blaschke M., Fischer H.D., Rudolph E. Effect of reserpine on monoamine uptake by rat brain synaptosomes. Acta Biol. Med. Ger. 39:1980;1205-1212.
3. Bowyer J.F., Spuhler K.P., Weiner N. Effects of phencyclidine, amphetamine and related compounds on dopamine release from and uptake into striatal synaptosomes. J. Pharmacol. Exp. Ther. 229:1984;671-680.
4. Brown J.M., Hanson G.R., Fleckenstein A.E. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J. Pharmacol. Exp. Ther. 296:2001;762-767.
5. Ciliax B.J., Heilman C., Demchyshyn L.L., Pristupa Z.B., Ince E., Hersch S.M., Niznik H.B., Levey A.I. The dopamine transporter: immunochemical characterization and localization in brain. J. Neurosci. 15:1995;1714-1723.
6. Erickson J.D., Eiden L.E., Hoffman B.J. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc. Natl. Acad. Sci. U. S. A. 89:1992;10993-10997.
7. Fleckenstein A.E., Kopajtic T.A., Boja J.W., Carroll F.I., Kuhar M.J. Highly potent cocaine analogs cause long-lasting increases in locomotor activity. Eur. J. Pharmacol. 311:1996;109-114.
8. Fleckenstein A.E., Haughey H.M., Metzger R.R., Kokoshka J.M., Riddle E.L., Hanson J.E., Gibb J.W., Hanson G.R. Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur. J. Pharmacol. 382:1999;45-49.
9. Gainetdinov R.R., Fumagalli F., Wang Y.M., Jones S.R., Levey A.I., Miller G.W., Caron M.G. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J. Neurochem. 70:1998;1973-1978.
10. 3H)-catecholamines by homogenates of rat corpus striatum and cerebral cortex: effects of amphetamine analogues. Neuropharmacology. 12:1973;669-679.
11. 3H-reserpine levels in brains of normal and tetrabenzine-pretreated rats. Eur. J. Pharmacol. 2:1967;139-141.
12. Miller G.W., Erickson J.D., Perez J.T., Penland S.N., Mash D.C., Rye D.B., Levey A.I. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp. Neurol. 154:1999;138-148.
13. Norn S., Shore P.A. Further studies on the nature of persistent reserpine binding: evidence for reversible and irreversible binding. Biochem. Pharmacol. 20:1971;1291-1295.
14. Pifl C., Hornykiewicz O., Giros B., Caron M.G. Catecholamine transporters and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: studies comparing the cloned human noradrenaline and human dopamine transporter. J. Pharmacol. Exp. Ther. 277:1996;1437-1443.
15. 3H-dopamine accumulation in reserpinized and normal rat striatum. Acta Pharm. Toxicol. (Copenh.). 44:1979;329-335.
16. Saunders C., Ferrer J.V., Shi L., Chen J., Merrill G., Lamb M.E., Leeb-Lundberg L.M., Carvelli L., Javitch J.A., Galli A. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc. Natl. Acad. Sci. U. S. A. 97:2000;6850-6855.
17. Wang Y.M., Gainetdinov R.R., Fumagalli F., Xu F., Jones S.R., Bock C.B., Miller G.W., Wightman R.M., Caron M.G. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron. 19:1997;1285-1296.